Department of Genitourinary Oncology Moffitt Cancer Center Tampa FL USA

Department of Medical Oncology Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy

Department of Surgery McGill University Health Center Montreal Canada

Department of Urology 2nd Faculty of Medicine Charles University Prague Czech Republic

Department of Urology and Kidney Transplant The University of Toledo Medical Center and Eleanor N Dana Cancer Center Toledo OH USA

Department of Urology Kantonsspital Winterthur Winterthur Switzerland

Department of Urology MD Anderson Cancer Center Houston TX USA

Department of Urology Medical University of Vienna Vienna Austria

Department of Urology Ohio State University Columbus OH USA

Department of Urology Seoul National University Hospital Seoul South Korea

Department of Urology The James Buchanan Brady Urological Institute The Johns Hopkins School of Medicine Baltimore MD USA

Department of Urology The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital Amsterdam The Netherlands

Department of Urology University Hospitals Leuven Leuven Belgium

Department of Urology University of Jordan Amman Jordan

Department of Urology University of Texas Southwestern Medical Center Dallas TX USA

Department of Urology Urological Research Institute Vita Salute University San Raffaele Scientific Institute Milan Italy

Department of Urology Weill Cornell Medical College New York NY USA

Institute for Urology and Reproductive Health 1 M Sechenov 1st Moscow State Medical University Moscow Russia

Karl Landsteiner Institute of Urology and Andrology Vienna Austria

Zobrazit více v PubMed

Rouprêt M., Babjuk M., Compérat E. European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2017 update. Eur Urol. 2018;73:111–122. doi: 10.1016/j.eururo.2017.07.036. PubMed DOI

Porten S., Siefker-Radtke A.O., Xiao L. Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. Cancer. 2014;120:1794–1799. doi: 10.1002/cncr.28655. PubMed DOI PMC

Kubota Y., Hatakeyama S., Tanaka T. Oncological outcomes of neoadjuvant chemotherapy in patients with locally advanced upper tract urothelial carcinoma: a multicenter study. Oncotarget. 2014;5:101500–101508. doi: 10.18632/oncotarget.21551. PubMed DOI PMC

Matin S.F., Margulis V., Kamat A. Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer. 2010;116:3127–3134. doi: 10.1002/cncr.25050. PubMed DOI

Hoffman-Censits J., Puligandla M., Trabulsi E. Phase II trial of neoadjuvant chemotherapy followed by extirpative surgery for patients with high grade upper tract urothelial carcinoma (HG UTUC): results from ECOG-ACRIN 8141. J Urol. 2018;199:e1166–e1167. doi: 10.1016/j.juro.2018.03.098. DOI

Rose T.L., Deal A.M., Nielsen M.E., Smith A.B., Milowsky M.I. Sex disparities in use of chemotherapy and survival in patients with advanced bladder cancer. Cancer. 2016;122:2012–2020. doi: 10.1002/cncr.30029. PubMed DOI PMC

D’Andrea D, Black PC, Zargar H, et al. Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer. Urol Oncol. In press. 10.1016/j.urolonc.2020.01.010 PubMed DOI

Shariat S.F., Favaretto R.L., Gupta A. Gender differences in radical nephroureterectomy for upper tract urothelial carcinoma. World J Urol. 2011;29:481–486. doi: 10.1007/s00345-010-0594-7. PubMed DOI

Lughezzani G., Sun M., Perrotte P. Gender-related differences in patients with stage I to III upper tract urothelial carcinoma: results from the Surveillance, Epidemiology, and End Results database. Urology. 2010;75:321–327. doi: 10.1016/j.urology.2009.09.048. PubMed DOI

Fernández M.I., Shariat S.F., Margulis V. Evidence-based sex-related outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: results of large multicenter study. Urology. 2009;73:142–146. doi: 10.1016/j.urology.2008.07.042. PubMed DOI